Fig. 3
From: A urine-based DNA methylation assay, ProCUrE, to identify clinically significant prostate cancer
Diagnostic and prognostic ability of ProCUrE and age-adjusted PSA in the validation cohort. a The percent false- and true-positive for ProCUrE or age-adjusted PSA separating benign and PCa patients. b The percent of patients positive for ProCUrE or age-adjusted PSA for clinically insignificant (benign and low-risk) vs clinically significant (intermediate- and high-risk) based on Gleason score. c, d The percent of patients positive for ProCUrE or age-adjusted PSA for clinically insignificant (benign and low-risk) vs clinically significant (intermediate- and high-risk) and low-risk vs intermediate- and high-risk as determined by CAPRA score and D’Amico. N = 140, χ2*p < 0.05, **p < 0.01, ***p < 0.001